The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach
Yixin Ningshen tablet is a CFDA-approved TCM formula for treating coronary heart disease (CHD) clinically. However, its active compounds and mechanism of action in treating CHD are unknown. In this study, a novel strategy with the combination of network pharmacology and proteomics was proposed to id...
Gespeichert in:
| Veröffentlicht in: | Evidence-based complementary and alternative medicine 2020, Vol.2020 (2020), p.1-17 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17 |
|---|---|
| container_issue | 2020 |
| container_start_page | 1 |
| container_title | Evidence-based complementary and alternative medicine |
| container_volume | 2020 |
| creator | Shen, Xiaoyan Wu, Ruoming Wang, Huijun Lv, Xing Ye, Guan |
| description | Yixin Ningshen tablet is a CFDA-approved TCM formula for treating coronary heart disease (CHD) clinically. However, its active compounds and mechanism of action in treating CHD are unknown. In this study, a novel strategy with the combination of network pharmacology and proteomics was proposed to identify the active components of Yixin Ningshen tablet and the mechanism by which they treat CHD. With the application of network pharmacology, 62 active compounds in Yixin Ningshen tablet were screened out by text mining, and their 313 potential target proteins were identified by a tool in SwissTargetPrediction. These data were integrated with known CHD-related proteomics results to predict the most possible targets, which reduced the 313 potential target proteins to 218. The STRING database was retrieved to find the enriched pathways and related diseases of these target proteins, which indicated that the Calcium, MAPK, PI3K-Akt, cAMP, Rap1, AGE-RAGE, Relaxin, HIF-1, Prolactin, Sphingolipid, Estrogen, IL-17, Jak-STAT signaling pathway, necroptosis, arachidonic acid metabolism, insulin resistance, endocrine resistance, and steroid hormone biosynthesis might be the main pathways regulated by Yixin Ningshen tablet for the treatment of CHD. Through further enrichment analysis and literature study, EGFR, ERBB2, VGFR2, FGF1, ESR1, LOX15, PGH2, HMDH, ADRB1, and ADRB2 were selected and then validated to be the target proteins of Yixin Ningshen tablet by molecular docking, which indicated that Yixin Ningshen tablet might treat CHD mainly through promoting heart regeneration, new vessels’ formation, and the blood supply of the myocardial region and reducing cardiac output, oxygen demand, and inflammation as well as arteriosclerosis (promoting vasodilation and intraplaque neoangiogenesis, lowering blood lipid). This study is expected to benefit the clinical application of Yixin Ningshen tablet for the treatment of CHD. |
| doi_str_mv | 10.1155/2020/4912395 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7204378</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A622555852</galeid><sourcerecordid>A622555852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-a974d42a77a89686774f39985f2823b48f8891baf1164390aff39fb513388dc43</originalsourceid><addsrcrecordid>eNqNkktv1DAUhSMEoqWwY40ssUGCUD9je1NpNDyKVMosBglW1p3Embgk9mBnWvqD-J94HkyBFStbut859tE9RfGU4NeECHFKMcWnXBPKtLhXHBPJScmpUvcPd_nlqHiU0hXGVEspHxZHjHKiFa6Oi5_zzqJJPbpri6ZhWIW1bxIKLfrqfjiPLp1fps56NIdFb0cEvkFZ4SKahdH60UG_VQePPtq6A-_SgLJuHi2MWZs9Y_AQb9G5hTiiNy5ZSLZEE3Rpx5sQv6FZB3GAOvRhebv1n8VsHQZXJzRZrWKAuntcPGihT_bJ_jwpPr97O5-elxef3n-YTi7Kmms9lqAlbzgFKUHpSlVS8pZprURLFWULrlqlNFlAS0jFmcbQ5nG7EIQxpZqas5PibOe7Wi8G29Q5YYTerKIbcgYTwJm_J951ZhmujaSYM6mywYu9QQzf1zaNZnCptn0P3oZ1MpRvuby3jD7_B70K6-hzPEOZwDgvj_E7agm9Nc63Ib9bb0zNpKJUCKEEzdSrHVXHkFK07eHLBJtNS8ymJWbfkow_-zPmAf5diwy83AGd8w3cuP-0s5mxLdzRRFSMCPYLMD7OmA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350017434</pqid></control><display><type>article</type><title>The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Shen, Xiaoyan ; Wu, Ruoming ; Wang, Huijun ; Lv, Xing ; Ye, Guan</creator><contributor>Calapai, Gioacchino ; Gioacchino Calapai</contributor><creatorcontrib>Shen, Xiaoyan ; Wu, Ruoming ; Wang, Huijun ; Lv, Xing ; Ye, Guan ; Calapai, Gioacchino ; Gioacchino Calapai</creatorcontrib><description>Yixin Ningshen tablet is a CFDA-approved TCM formula for treating coronary heart disease (CHD) clinically. However, its active compounds and mechanism of action in treating CHD are unknown. In this study, a novel strategy with the combination of network pharmacology and proteomics was proposed to identify the active components of Yixin Ningshen tablet and the mechanism by which they treat CHD. With the application of network pharmacology, 62 active compounds in Yixin Ningshen tablet were screened out by text mining, and their 313 potential target proteins were identified by a tool in SwissTargetPrediction. These data were integrated with known CHD-related proteomics results to predict the most possible targets, which reduced the 313 potential target proteins to 218. The STRING database was retrieved to find the enriched pathways and related diseases of these target proteins, which indicated that the Calcium, MAPK, PI3K-Akt, cAMP, Rap1, AGE-RAGE, Relaxin, HIF-1, Prolactin, Sphingolipid, Estrogen, IL-17, Jak-STAT signaling pathway, necroptosis, arachidonic acid metabolism, insulin resistance, endocrine resistance, and steroid hormone biosynthesis might be the main pathways regulated by Yixin Ningshen tablet for the treatment of CHD. Through further enrichment analysis and literature study, EGFR, ERBB2, VGFR2, FGF1, ESR1, LOX15, PGH2, HMDH, ADRB1, and ADRB2 were selected and then validated to be the target proteins of Yixin Ningshen tablet by molecular docking, which indicated that Yixin Ningshen tablet might treat CHD mainly through promoting heart regeneration, new vessels’ formation, and the blood supply of the myocardial region and reducing cardiac output, oxygen demand, and inflammation as well as arteriosclerosis (promoting vasodilation and intraplaque neoangiogenesis, lowering blood lipid). This study is expected to benefit the clinical application of Yixin Ningshen tablet for the treatment of CHD.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2020/4912395</identifier><identifier>PMID: 32419806</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>1-Phosphatidylinositol 3-kinase ; Acids ; AKT protein ; Arachidonic acid ; Arteriosclerosis ; Binding sites ; Calcium ; Cardiovascular disease ; Chinese medicine ; Coronary artery disease ; Coronary heart disease ; Data mining ; Drug therapy ; Epidermal growth factor receptors ; ErbB-2 protein ; Estrogen receptors ; Evidence-based medicine ; Fibroblast growth factor 1 ; Fibroblast growth factors ; Heart diseases ; Insulin ; Insulin resistance ; Interleukin 17 ; MAP kinase ; Medicine, Chinese ; Necroptosis ; Neovascularization ; Pharmacology ; Physiological aspects ; Prolactin ; Proteins ; Proteomics ; Rap1 protein ; Relaxin ; Signal transduction ; Steroid hormones ; Unsaturated fatty acids ; Vasodilation ; Wu Wei</subject><ispartof>Evidence-based complementary and alternative medicine, 2020, Vol.2020 (2020), p.1-17</ispartof><rights>Copyright © 2020 Xing Lv et al.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>Copyright © 2020 Xing Lv et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Xing Lv et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-a974d42a77a89686774f39985f2823b48f8891baf1164390aff39fb513388dc43</citedby><cites>FETCH-LOGICAL-c499t-a974d42a77a89686774f39985f2823b48f8891baf1164390aff39fb513388dc43</cites><orcidid>0000-0001-6794-9972 ; 0000-0002-0476-6789 ; 0000-0003-4828-3268 ; 0000-0001-6319-498X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204378/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204378/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4022,27922,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32419806$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Calapai, Gioacchino</contributor><contributor>Gioacchino Calapai</contributor><creatorcontrib>Shen, Xiaoyan</creatorcontrib><creatorcontrib>Wu, Ruoming</creatorcontrib><creatorcontrib>Wang, Huijun</creatorcontrib><creatorcontrib>Lv, Xing</creatorcontrib><creatorcontrib>Ye, Guan</creatorcontrib><title>The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach</title><title>Evidence-based complementary and alternative medicine</title><addtitle>Evid Based Complement Alternat Med</addtitle><description>Yixin Ningshen tablet is a CFDA-approved TCM formula for treating coronary heart disease (CHD) clinically. However, its active compounds and mechanism of action in treating CHD are unknown. In this study, a novel strategy with the combination of network pharmacology and proteomics was proposed to identify the active components of Yixin Ningshen tablet and the mechanism by which they treat CHD. With the application of network pharmacology, 62 active compounds in Yixin Ningshen tablet were screened out by text mining, and their 313 potential target proteins were identified by a tool in SwissTargetPrediction. These data were integrated with known CHD-related proteomics results to predict the most possible targets, which reduced the 313 potential target proteins to 218. The STRING database was retrieved to find the enriched pathways and related diseases of these target proteins, which indicated that the Calcium, MAPK, PI3K-Akt, cAMP, Rap1, AGE-RAGE, Relaxin, HIF-1, Prolactin, Sphingolipid, Estrogen, IL-17, Jak-STAT signaling pathway, necroptosis, arachidonic acid metabolism, insulin resistance, endocrine resistance, and steroid hormone biosynthesis might be the main pathways regulated by Yixin Ningshen tablet for the treatment of CHD. Through further enrichment analysis and literature study, EGFR, ERBB2, VGFR2, FGF1, ESR1, LOX15, PGH2, HMDH, ADRB1, and ADRB2 were selected and then validated to be the target proteins of Yixin Ningshen tablet by molecular docking, which indicated that Yixin Ningshen tablet might treat CHD mainly through promoting heart regeneration, new vessels’ formation, and the blood supply of the myocardial region and reducing cardiac output, oxygen demand, and inflammation as well as arteriosclerosis (promoting vasodilation and intraplaque neoangiogenesis, lowering blood lipid). This study is expected to benefit the clinical application of Yixin Ningshen tablet for the treatment of CHD.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>Acids</subject><subject>AKT protein</subject><subject>Arachidonic acid</subject><subject>Arteriosclerosis</subject><subject>Binding sites</subject><subject>Calcium</subject><subject>Cardiovascular disease</subject><subject>Chinese medicine</subject><subject>Coronary artery disease</subject><subject>Coronary heart disease</subject><subject>Data mining</subject><subject>Drug therapy</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB-2 protein</subject><subject>Estrogen receptors</subject><subject>Evidence-based medicine</subject><subject>Fibroblast growth factor 1</subject><subject>Fibroblast growth factors</subject><subject>Heart diseases</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Interleukin 17</subject><subject>MAP kinase</subject><subject>Medicine, Chinese</subject><subject>Necroptosis</subject><subject>Neovascularization</subject><subject>Pharmacology</subject><subject>Physiological aspects</subject><subject>Prolactin</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Rap1 protein</subject><subject>Relaxin</subject><subject>Signal transduction</subject><subject>Steroid hormones</subject><subject>Unsaturated fatty acids</subject><subject>Vasodilation</subject><subject>Wu Wei</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkktv1DAUhSMEoqWwY40ssUGCUD9je1NpNDyKVMosBglW1p3Embgk9mBnWvqD-J94HkyBFStbut859tE9RfGU4NeECHFKMcWnXBPKtLhXHBPJScmpUvcPd_nlqHiU0hXGVEspHxZHjHKiFa6Oi5_zzqJJPbpri6ZhWIW1bxIKLfrqfjiPLp1fps56NIdFb0cEvkFZ4SKahdH60UG_VQePPtq6A-_SgLJuHi2MWZs9Y_AQb9G5hTiiNy5ZSLZEE3Rpx5sQv6FZB3GAOvRhebv1n8VsHQZXJzRZrWKAuntcPGihT_bJ_jwpPr97O5-elxef3n-YTi7Kmms9lqAlbzgFKUHpSlVS8pZprURLFWULrlqlNFlAS0jFmcbQ5nG7EIQxpZqas5PibOe7Wi8G29Q5YYTerKIbcgYTwJm_J951ZhmujaSYM6mywYu9QQzf1zaNZnCptn0P3oZ1MpRvuby3jD7_B70K6-hzPEOZwDgvj_E7agm9Nc63Ib9bb0zNpKJUCKEEzdSrHVXHkFK07eHLBJtNS8ymJWbfkow_-zPmAf5diwy83AGd8w3cuP-0s5mxLdzRRFSMCPYLMD7OmA</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Shen, Xiaoyan</creator><creator>Wu, Ruoming</creator><creator>Wang, Huijun</creator><creator>Lv, Xing</creator><creator>Ye, Guan</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6794-9972</orcidid><orcidid>https://orcid.org/0000-0002-0476-6789</orcidid><orcidid>https://orcid.org/0000-0003-4828-3268</orcidid><orcidid>https://orcid.org/0000-0001-6319-498X</orcidid></search><sort><creationdate>2020</creationdate><title>The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach</title><author>Shen, Xiaoyan ; Wu, Ruoming ; Wang, Huijun ; Lv, Xing ; Ye, Guan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-a974d42a77a89686774f39985f2823b48f8891baf1164390aff39fb513388dc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>Acids</topic><topic>AKT protein</topic><topic>Arachidonic acid</topic><topic>Arteriosclerosis</topic><topic>Binding sites</topic><topic>Calcium</topic><topic>Cardiovascular disease</topic><topic>Chinese medicine</topic><topic>Coronary artery disease</topic><topic>Coronary heart disease</topic><topic>Data mining</topic><topic>Drug therapy</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB-2 protein</topic><topic>Estrogen receptors</topic><topic>Evidence-based medicine</topic><topic>Fibroblast growth factor 1</topic><topic>Fibroblast growth factors</topic><topic>Heart diseases</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Interleukin 17</topic><topic>MAP kinase</topic><topic>Medicine, Chinese</topic><topic>Necroptosis</topic><topic>Neovascularization</topic><topic>Pharmacology</topic><topic>Physiological aspects</topic><topic>Prolactin</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Rap1 protein</topic><topic>Relaxin</topic><topic>Signal transduction</topic><topic>Steroid hormones</topic><topic>Unsaturated fatty acids</topic><topic>Vasodilation</topic><topic>Wu Wei</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shen, Xiaoyan</creatorcontrib><creatorcontrib>Wu, Ruoming</creatorcontrib><creatorcontrib>Wang, Huijun</creatorcontrib><creatorcontrib>Lv, Xing</creatorcontrib><creatorcontrib>Ye, Guan</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shen, Xiaoyan</au><au>Wu, Ruoming</au><au>Wang, Huijun</au><au>Lv, Xing</au><au>Ye, Guan</au><au>Calapai, Gioacchino</au><au>Gioacchino Calapai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><addtitle>Evid Based Complement Alternat Med</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>17</epage><pages>1-17</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Yixin Ningshen tablet is a CFDA-approved TCM formula for treating coronary heart disease (CHD) clinically. However, its active compounds and mechanism of action in treating CHD are unknown. In this study, a novel strategy with the combination of network pharmacology and proteomics was proposed to identify the active components of Yixin Ningshen tablet and the mechanism by which they treat CHD. With the application of network pharmacology, 62 active compounds in Yixin Ningshen tablet were screened out by text mining, and their 313 potential target proteins were identified by a tool in SwissTargetPrediction. These data were integrated with known CHD-related proteomics results to predict the most possible targets, which reduced the 313 potential target proteins to 218. The STRING database was retrieved to find the enriched pathways and related diseases of these target proteins, which indicated that the Calcium, MAPK, PI3K-Akt, cAMP, Rap1, AGE-RAGE, Relaxin, HIF-1, Prolactin, Sphingolipid, Estrogen, IL-17, Jak-STAT signaling pathway, necroptosis, arachidonic acid metabolism, insulin resistance, endocrine resistance, and steroid hormone biosynthesis might be the main pathways regulated by Yixin Ningshen tablet for the treatment of CHD. Through further enrichment analysis and literature study, EGFR, ERBB2, VGFR2, FGF1, ESR1, LOX15, PGH2, HMDH, ADRB1, and ADRB2 were selected and then validated to be the target proteins of Yixin Ningshen tablet by molecular docking, which indicated that Yixin Ningshen tablet might treat CHD mainly through promoting heart regeneration, new vessels’ formation, and the blood supply of the myocardial region and reducing cardiac output, oxygen demand, and inflammation as well as arteriosclerosis (promoting vasodilation and intraplaque neoangiogenesis, lowering blood lipid). This study is expected to benefit the clinical application of Yixin Ningshen tablet for the treatment of CHD.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>32419806</pmid><doi>10.1155/2020/4912395</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0001-6794-9972</orcidid><orcidid>https://orcid.org/0000-0002-0476-6789</orcidid><orcidid>https://orcid.org/0000-0003-4828-3268</orcidid><orcidid>https://orcid.org/0000-0001-6319-498X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1741-427X |
| ispartof | Evidence-based complementary and alternative medicine, 2020, Vol.2020 (2020), p.1-17 |
| issn | 1741-427X 1741-4288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7204378 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
| subjects | 1-Phosphatidylinositol 3-kinase Acids AKT protein Arachidonic acid Arteriosclerosis Binding sites Calcium Cardiovascular disease Chinese medicine Coronary artery disease Coronary heart disease Data mining Drug therapy Epidermal growth factor receptors ErbB-2 protein Estrogen receptors Evidence-based medicine Fibroblast growth factor 1 Fibroblast growth factors Heart diseases Insulin Insulin resistance Interleukin 17 MAP kinase Medicine, Chinese Necroptosis Neovascularization Pharmacology Physiological aspects Prolactin Proteins Proteomics Rap1 protein Relaxin Signal transduction Steroid hormones Unsaturated fatty acids Vasodilation Wu Wei |
| title | The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T01%3A50%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Active%20Compounds%20of%20Yixin%20Ningshen%20Tablet%20and%20Their%20Potential%20Action%20Mechanism%20in%20Treating%20Coronary%20Heart%20Disease-%20A%20Network%20Pharmacology%20and%20Proteomics%20Approach&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Shen,%20Xiaoyan&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=17&rft.pages=1-17&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2020/4912395&rft_dat=%3Cgale_pubme%3EA622555852%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350017434&rft_id=info:pmid/32419806&rft_galeid=A622555852&rfr_iscdi=true |